2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text (Rapid PDF) All Versions of this Article: ASN.2005101075v1 ASN.2005101075v2 17/2/339    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Caramori, M. L. Articles by Mauer, M. Search for Related Content PubMed PubMed Citation Articles by Caramori, M. L. Articles by Mauer, M.

FRONTIERS IN NEPHROLOGY

Enhancing the Predictive Value of Urinary Albumin for Diabetic Nephropathy

M. Luiza Caramori ^*, Paola Fioretto , and Michael Mauer ¹

Departments of *Medicine and Pediatrics, University of Minnesota, Minneapolis, Minnesota; and Department of Medical and Surgical Sciences, University of Padova, Padova, Italy

¹ To whom correspondence should be addressed. E-mail: mauer002{at}umn.edu.

	Abstract

Diabetic nephropathy (DN) is a growing cause of ESRD despite widely known recommendations for improved glycemic and BP control. Perhaps earlier identification of patients who have diabetes and are at high risk for DN could reverse these epidemiologic trends. Albumin excretion rate (AER), the mainstay of early detection of DN, is not a sufficiently precise predictor of DN risk. Careful family history, smoking history, consideration of absolute versus categorical AER values, more frequent AER measures, ambulatory BP monitoring, precise GFR measurements, diabetic retinopathy assessments, and plasma lipid levels all can add to predictive accuracy for DN. Thus, although further research in DN biomarkers and predictors is greatly needed, a careful integrated evaluation of currently available parameters can improve our ability to predict DN risk in individual patients.

This article has been cited by other articles:

				L. D. Bash, E. Selvin, M. Steffes, J. Coresh, and B. C. Astor Poor Glycemic Control in Diabetes and the Risk of Incident Chronic Kidney Disease Even in the Absence of Albuminuria and Retinopathy: Atherosclerosis Risk in Communities (ARIC) Study Arch Intern Med, December 8, 2008; 168(22): 2440 - 2447. [Abstract] [Full Text] [PDF]

				A. Dixon and C. Maric 17beta-Estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor-beta protein expression and signaling Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1678 - F1690. [Abstract] [Full Text] [PDF]

				B. A. Perkins, L. H. Ficociello, B. E. Ostrander, K. H. Silva, J. Weinberg, J. H. Warram, and A. S. Krolewski Microalbuminuria and the Risk for Early Progressive Renal Function Decline in Type 1 Diabetes J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1353 - 1361. [Abstract] [Full Text] [PDF]

				J. R. Sedor Frontiers in Diabetic Nephropathy: Can We Predict Who Will Get Sick? J. Am. Soc. Nephrol., February 1, 2006; 17(2): 336 - 338. [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673